[KH explains] Why Korea has been so quick to adopt ‘global minimum tax’
Health services disrupted as mass walkout by trainee doctors approaches deadline
[Today’s K-pop] Karina of aespa is dating actor Lee Jae-wook: report
South Korea’s fertility rate drops to new low
[Chung Chan-seung] The collapse of trust: South Korea's true health care crisis
[Herald Interview] Rival heir to Kim Ju-ae unlikely to appear: unification minister
Russia sending North Korea food in return for arms: Seoul defense chief
University ranking hierarchy leads to wage gap later in life: study
US Navy secretary scouts Korean shipbuilders for fleet support
Interior minister renews calls for trainee doctors to return to work
Celltrion cautious against COVID-19 spread as treatment nears approvalBy Lim Jeong-yeo
Published : Nov. 30, 2020 - 14:00
“Employees at Celltrion are now advised to take their work laptops home with them every day, so that in the case we become confirmed patients, we can immediately work from home under quarantine,” a Celltrion employee told The Korea Herald under the condition of anonymity. There have been no confirmed cases within the company.
Celltrion staff are receiving daily emails from the company warning them to “not become the first confirmed case from Celltrion.”
Incheon marked 34 additional confirmed patients on Monday.
The Yeonsu-gu regional office recorded an accumulated 168 confirmed patients Sunday. Among them, 114 were declared as having been released after recovery; 54 were being treated. Those who are self-quarantining as a preventive measure after overlapping with patients’ movement routes amounted to 930.
According to the source from Celltrion, there is a companywide perception that they are days away from the Ministry of Food and Drug Safety’s approval for Celltrion’s CT-P59 antibody treatment for COVID-19. Employees are working around the clock preparing approval application documents for the Drug Ministry.
On Wednesday, Celltrion said through an official press release that it had finished administering CT-P59 (regdanvimab) in 327 patients enrolled in its clinical phase 2 trial conducted across Korea, the US, Romania and Spain.
Celltrion Chairperson Seo Jung-jin personally vowed in an interview with a local media that CT-P59 will be available early next year.
By Lim Jeong-yeo (firstname.lastname@example.org)
[KH Explains] What does Apple's dead car project mean for Samsung, Hyundai?
Yoon, Zuckerberg discuss AI, digital ecosystem in Seoul
Cho, Blinken pledge 'watertight' response to any NK provocations